Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04297020 · ClinicalTrials.gov registry record
Brain Health in Breast Cancer Survivors
A clinical trial of Cognitive Impairment and Cognitive Function, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT04297020: Recruiting study of Cognitive Impairment and Cognitive Function, sponsored by Jonsson Comprehensive Cancer Center.
NCT04297020 is a study of Cognitive Impairment and Cognitive Function that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 120 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04297020, a study of Cognitive Impairment and Cognitive Function, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Endocrine therapy (ET) is widely used to treat hormone receptor positive breast cancer and prevent recurrence by downregulating estrogen function. However, ETs readily cross the blood brain barrier and interfere with the action of estrogen in the brain. Estrogen supports cognition and menopausal status is closely linked to cognitive health in women. This has raised concern that anti-estrogen ETs may affect cognition and brain health in breast cancer survivors. However, evidence across existing studies is inconsistent and these effects remain poorly understood. The incomplete understanding of the effects of ET are likely due to limitations of earlier studies - namely, the under-appreciation of the role of menopausal status and insensitivity of standard cognitive measures. This research project will address these earlier limitations by specifically comparing ET effects by menopausal status, and using highly sensitive, task-related functional magnetic resonance imaging (fMRI) measures to assess the effects of ET on brain function.
Primary Outcome
To compare brain activity using fMRI during a working memory task between breast cancer survivors on ET and matched healthy controls, and examine the interaction of menopausal status.
Conditions Studied
Study Locations (1)
California
- University of California at Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-03-11 |
| Est. Completion | 2027-03-15 |
What NCT04297020 shows while recruiting
NCT04297020 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.
NCT04297020 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04297020 about?
NCT04297020 is a clinical study titled "Brain Health in Breast Cancer Survivors". Endocrine therapy (ET) is widely used to treat hormone receptor positive breast cancer and prevent recurrence by downregulating estrogen function. However, ETs readily cross the blood brain barrier and interfere with the action of estrogen in the brain. Estrogen supports cognition and menopausal sta...
What is the current status of trial NCT04297020?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2020-03-11. Estimated completion is 2027-03-15.
What conditions does trial NCT04297020 study?
This clinical trial studies the following conditions: Cognitive Impairment, Cognitive Function.
Who is sponsoring clinical trial NCT04297020?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04297020 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04297020's enrollment target sits among peer trials
120 34th of 105 higher than 70 of 105 other Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI